288 related articles for article (PubMed ID: 31478094)
21. Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
[TBL] [Abstract][Full Text] [Related]
22. Incorporating clinical monitoring into electronic orders for antipsychotics.
Roche-Desilets J; Fuller MA; Konicki PE
Psychiatr Serv; 2004 Apr; 55(4):455. PubMed ID: 15067165
[No Abstract] [Full Text] [Related]
23. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort).
Ter Hark SE; Jamain S; Schijven D; Lin BD; Bakker MK; Boland-Auge A; Deleuze JF; Troudet R; Malhotra AK; Gülöksüz S; Vinkers CH; Ebdrup BH; Kahn RS; Leboyer M; Luykx JJ
J Psychopharmacol; 2020 May; 34(5):524-531. PubMed ID: 32126890
[TBL] [Abstract][Full Text] [Related]
24. Metabolic consequences of atypical antipsychotic drugs.
Lebovitz HE
Psychiatr Q; 2003; 74(3):277-90. PubMed ID: 12918602
[TBL] [Abstract][Full Text] [Related]
25. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
Deng C
Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
[TBL] [Abstract][Full Text] [Related]
26. [Antipsychotic drugs. Risk factors for diabetes].
Stip E; Tranulis C; Légaré N; Poulin MJ
Presse Med; 2003 Oct; 32(34):1612-7. PubMed ID: 14576587
[TBL] [Abstract][Full Text] [Related]
27. Identifying metabolic risks with antipsychotics and monitoring and management strategies.
Newcomer JW; Sernyak MJ
J Clin Psychiatry; 2007 Jul; 68(7):e17. PubMed ID: 17685728
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs.
Lamberti JS; Crilly JF; Maharaj K; Olson D; Wiener K; Dvorin S; Costea GO; Bushey MP; Dietz MB
J Clin Psychiatry; 2004 May; 65(5):702-6. PubMed ID: 15163259
[TBL] [Abstract][Full Text] [Related]
29. [Diabetes mellitus and atypical antipsychotics].
de Sena EP; Sampaio AS; Quarantini Lde C; Oliveira IR
Braz J Psychiatry; 2003 Oct; 25(4):253-7. PubMed ID: 15328554
[TBL] [Abstract][Full Text] [Related]
30. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
[TBL] [Abstract][Full Text] [Related]
31. The medical care of people with psychosis.
Lambert TJ
Med J Aust; 2009 Feb; 190(4):171-2. PubMed ID: 19220177
[No Abstract] [Full Text] [Related]
32. No mental health without physical health.
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2011 Feb; 377(9766):611. PubMed ID: 21334517
[No Abstract] [Full Text] [Related]
33. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
34. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
Pallava A; Chadda RK; Sood M; Lakshmy R
Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
[TBL] [Abstract][Full Text] [Related]
35. Side effects of atypical antipsychotic drugs.
Ananth J; Parameswaran S; Gunatilake S
Curr Pharm Des; 2004; 10(18):2219-29. PubMed ID: 15281897
[TBL] [Abstract][Full Text] [Related]
36. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
[TBL] [Abstract][Full Text] [Related]
37. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
[TBL] [Abstract][Full Text] [Related]
38. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain.
Grajales D; Ferreira V; Valverde ÁM
Cells; 2019 Oct; 8(11):. PubMed ID: 31671770
[TBL] [Abstract][Full Text] [Related]
39. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms.
Gonçalves P; Araújo JR; Martel F
Eur Neuropsychopharmacol; 2015 Jan; 25(1):1-16. PubMed ID: 25523882
[TBL] [Abstract][Full Text] [Related]
40. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
